News
AKTX
3.180
-3.64%
-0.120
Weekly Report: what happened at AKTX last week (0902-0906)?
Weekly Report · 4d ago
AKARI THERAPEUTICS FILES PROSPECTUS FOR RESALE BY SELLING SHAREHOLDERS OF UP TO 21.56 BLN ORDINARY SHARES - SEC FILING
Reuters · 6d ago
Weekly Report: what happened at AKTX last week (0826-0830)?
Weekly Report · 09/02 10:00
Weekly Report: what happened at AKTX last week (0819-0823)?
Weekly Report · 08/26 09:59
Based on the provided financial report articles, the title of the article is: "FORM 10-Q" This is a quarterly report filed by Akari Therapeutics, Plc with the United States Securities and Exchange Commission (SEC) for the quarter ended June 30, 2024.
Press release · 08/19 23:16
AKARI THERAPEUTICS: SAMIR R. PATEL, M.D. APPOINTED AS INTERIM CEO
Reuters · 08/19 20:38
Akari Therapeutics Appoints Samir R. Patel As Interim CEO; Plans For Prioritization Of Peak Bio's ADC Cancer Therapeutic Platform Technology And Akari's PAS-Nomacopan For Geographic Atrophy
Benzinga · 08/19 20:26
Akari Therapeutics GAAP EPS of $0.00
Seeking Alpha · 08/19 20:22
AKARI THERAPEUTICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND RECENT HIGHLIGHTS
Reuters · 08/19 20:15
AKARI THERAPEUTICS H1 NET INCOME USD -13.124 MILLION
Reuters · 08/19 20:15
Akari Therapeutics Receives FDA Feedback, Paving the Way for New Eye Disease Treatment
Benzinga · 08/19 12:02
AKARI THERAPEUTICS: REGULATORY FEEDBACK FROM FDA, PRODUCTION OF GMP MATERIAL ENABLES PATH FORWARD TO SUBMITTING IND
Reuters · 08/19 12:00
AKARI THERAPEUTICS RECEIVES POSITIVE AND CONSTRUCTIVE PRE-IND FEEDBACK FROM US FDA FOR PAS-NOMACOPAN IN TREATMENT OF GEOGRAPHIC ATROPHY
Reuters · 08/19 12:00
Weekly Report: what happened at AKTX last week (0812-0816)?
Weekly Report · 08/19 09:54
Weekly Report: what happened at AKTX last week (0805-0809)?
Weekly Report · 08/12 09:55
Weekly Report: what happened at AKTX last week (0729-0802)?
Weekly Report · 08/05 09:59
Weekly Report: what happened at AKTX last week (0722-0726)?
Weekly Report · 07/29 09:55
Weekly Report: what happened at AKTX last week (0715-0719)?
Weekly Report · 07/22 09:56
Weekly Report: what happened at AKTX last week (0708-0712)?
Weekly Report · 07/15 09:54
Weekly Report: what happened at AKTX last week (0701-0705)?
Weekly Report · 07/08 09:55
More
Webull provides a variety of real-time AKTX stock news. You can receive the latest news about Akari Therapeutics Plc through multiple platforms. This information may help you make smarter investment decisions.
About AKTX
Akari Therapeutics, Plc is a late-stage biotechnology company. The Company is developing advanced therapies for autoimmune and inflammatory diseases. Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Its pipeline includes a Phase 3 clinical trial program investigating nomacopan for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). It is conducting a clinical trial of subcutaneous nomacopan for the treatment of HSCT-TMA in pediatrics. The United States Food and Drug Administration (FDA) has granted Rare Pediatric Disease, Orphan Drug, and Fast Track designations to nomacopan for the treatment of pediatric HSCT-TMA. It is also investigating long-acting PASylated-nomacopan (PAS-nomacopan) for treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD) in preclinical studies.